MOUNTAIN VIEW, Calif., August 13, 2025–Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported financial results for the quarter ended June 30, 2025, and highlighted recent progress across its pipeline of clinical-stage product candidates.Read More
Alto Neuroscience Reports Second Quarter 2025 Financial Results and Recent Business Highlights
